New Product Addresses Impaired Absorption and Increased Nutritional Requirements of Autism
Los Angeles, CA, August 30, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) today announced that the company will begin a clinical trial on a new medical food indicated for the dietary management of Autism and Autism Spectrum Disorders.
This open label trial will measure the changes in blood concentrations of specific amino acids, behavior, mood, and sleep patterns over a thirty day period following a twice daily oral administration of the company’s new medical food. Subjects will be screened for enrollment based on medical history and diagnosis of Autism or any Autism Spectrum Disorders.
“Autism and Autistic Spectrum have long been recognized to be associated with reduced absorption of amino acids and a decrease in several brain neurotransmitters. With our targeted cellular technology platform, we believe that this product may be able to increase the concentration of the necessary amino acid precursors and brain neurotransmitters that are diminshed in patients with autism,” said David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma, Inc. “Our company has established that treating an underlying nutritional deficiency of a disease with a medical food can greatly reduce symptoms and improve clinical outcomes.”
Autism and Autism Spectrum Disorders affect one percent of the population of children in the U.S. ages three to seventeen, with an estimated prevalence of one out of eighty eight births in the U.S. being affected by the disease. The current pharmacologic treatments available are ineffective at treating the disease and are often associated with adverse side effects.
About Targeted Cellular Technology
Targeted cellular technology is a patented five-step process that is the foundation for the company’s medical foods. This technology promotes the rapid cellular uptake, conversion and release of neurotransmitter precursors, prevents attenuation and increases the efficacy of milligram quantities of amino acids, nutrients and biogenic amines.
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also is engaged in the development of a proprietary line of dietary supplements.
Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.
# # #